FBLG net incomeQ2 2026-$4.12M
FBLG net income was -$4.12M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.66M a year earlier. For the full fiscal 2025 it was -$18.65M, compared with -$11.16M in fiscal 2024.
FibroBiologics Inc. (FBLG) financials
For the twelve months ended Jun 30, 2026, FibroBiologics Inc. reported -$18.14M of net income.
- Net income, TTM
- -$18.14M
- Free cash flow, TTM
- -$14.80M
- Cash
- $3.52M
- Market cap
- $6.5M
FY2022FY2025
FY2023FY2025
FBLG revenue and earnings growth
FBLG EPSQ2 2026-$0.66
FBLG diluted EPS was -$0.66 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$8.40, compared with -$6.80 in fiscal 2024.
FBLG free cash flowQ2 2026-$3.29M
FBLG free cash flow was -$3.29M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.20M a year earlier. For the full fiscal 2025 it was -$16.66M, compared with -$12.09M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $7.41M | $4.50M | $2.37M | $1.15M |
| Selling, general and admin | $9.24M | $9.23M | $6.52M | $3.32M |
| Operating income | -$16.65M | -$13.74M | -$8.89M | -$4.47M |
| Interest expense | - | - | $147.0K | $654.0K |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$18.65M | -$11.16M | -$16.48M | -$5.12M |
| EPS, basic | -$8.40 | -$6.80 | -$13.60 | -$3.60 |
| EPS, diluted | -$8.40 | -$6.80 | -$13.60 | -$3.60 |
| Diluted shares | 2.2M | 1.6M | 1.4M | 1.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $4.89M | $13.98M | $9.16M | $2.27M |
| Receivables | - | - | - | $300.0K |
| Current assets | $6.35M | $14.23M | $9.21M | $2.63M |
| Total assets | $9.62M | $16.45M | $11.82M | $4.82M |
| Current liabilities | $1.76M | $12.73M | $9.18M | $7.07M |
| Total liabilities | $3.46M | $13.71M | $10.57M | $8.82M |
| Shareholders' equity | $6.16M | $2.73M | $1.25M | -$4.00M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$16.39M | -$11.90M | -$6.40M | -$4.07M |
| Capital expenditures | $262.0K | $184.0K | $495.0K | - |
| Free cash flow | -$16.66M | -$12.09M | -$6.90M | - |
| Investing cash flow | -$262.0K | -$184.0K | -$495.0K | - |
| Financing cash flow | $7.57M | $16.91M | $13.79M | $5.92M |
| Stock-based compensation | $2.69M | $2.22M | $1.76M | $265.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.66M | $2.95M | $797.0K | $2.79M | $2.04M | $1.78M | $1.36M | $1.21M | $975.0K | $960.0K | $773.0K | $571.0K |
| Selling, general and admin | $2.38M | $2.12M | $1.79M | $2.25M | $2.45M | $2.75M | $2.36M | $2.14M | $2.25M | $2.49M | $1.71M | $1.48M |
| Operating income | -$4.03M | -$5.07M | -$2.59M | -$5.04M | -$4.49M | -$4.53M | -$3.71M | -$3.35M | -$3.22M | -$3.45M | -$2.48M | -$2.05M |
| Interest expense | - | - | - | - | - | - | - | - | $5.0K | $4.0K | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - | - |
| Net income | -$4.12M | -$5.00M | -$3.24M | -$5.78M | -$4.66M | -$4.97M | -$3.10M | -$500.0K | $898.0K | -$8.46M | -$9.72M | -$2.19M |
| EPS, basic | -$0.66 | -$1.33 | - | -$2.60 | -$2.41 | -$2.71 | -$1.80 | -$0.20 | $0.60 | -$5.40 | -$6.80 | -$1.60 |
| EPS, diluted | -$0.66 | -$1.33 | - | -$2.60 | -$2.41 | -$2.71 | -$1.80 | -$0.20 | $0.60 | -$5.40 | -$6.80 | -$1.60 |
| Diluted shares | 6.3M | 3.8M | - | 2.2M | 1.9M | 1.8M | - | 1.7M | 1.6M | 1.6M | - | 1.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.52M | $1.48M | $4.89M | $4.87M | $8.85M | $8.67M | $13.98M | $7.83M | $5.97M | $8.16M | $9.16M | $10.77M |
| Current assets | $5.85M | $2.90M | $6.35M | $5.24M | $10.18M | $9.33M | $14.23M | $8.20M | $6.51M | $8.92M | $9.21M | - |
| Total assets | $7.93M | $5.94M | $9.62M | $8.74M | $13.91M | $11.43M | $16.45M | $10.47M | $8.91M | $11.40M | $11.82M | - |
| Current liabilities | $2.21M | $1.83M | $1.76M | $6.72M | $10.96M | $8.21M | $12.73M | $6.68M | $10.13M | $13.98M | $9.18M | - |
| Total liabilities | $3.29M | $3.34M | $3.46M | $8.62M | $13.05M | $9.08M | $13.71M | $7.73M | $11.30M | $15.26M | $10.57M | - |
| Shareholders' equity | $4.64M | $2.60M | $6.16M | $125.0K | $860.0K | $2.35M | $2.73M | $2.74M | -$2.39M | -$3.86M | $1.25M | $10.54M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.29M | -$4.36M | -$3.16M | -$3.97M | -$3.98M | -$5.28M | -$3.07M | -$2.61M | -$1.95M | -$4.28M | -$1.60M | -$1.14M |
| Capital expenditures | $0 | $0 | $0 | $6.0K | $213.0K | $43.0K | $99.0K | $11.0K | $66.0K | $8.0K | $2.0K | $413.0K |
| Free cash flow | -$3.29M | -$4.36M | -$3.16M | -$3.98M | -$4.20M | -$5.32M | -$3.17M | -$2.62M | -$2.01M | -$4.28M | -$1.60M | -$1.55M |
| Investing cash flow | $0 | $0 | $0 | -$6.0K | -$213.0K | -$43.0K | -$99.0K | -$11.0K | -$66.0K | -$8.0K | -$2.0K | -$413.0K |
| Financing cash flow | $5.32M | $952.0K | $3.19M | $0 | $4.38M | $0 | $9.33M | $4.47M | -$172.0K | $3.28M | $0 | $940.0K |
| Stock-based compensation | $707.0K | $694.0K | $702.0K | $704.0K | $729.0K | $551.0K | $544.0K | $572.0K | $578.0K | $525.0K | $432.0K | $437.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.64 | 1.59 | 3.61 | 0.78 | 0.93 | 1.14 | 1.12 | 1.23 | 0.64 | 0.64 | 1.00 | - |
Source: XBRL data FibroBiologics Inc. files with the SEC, latest filing dated Jul 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Apr 30, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
FBLG peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| FBLG | - | - | -$18.14M | - | $6.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
FBLG FAQ
5 questionsIs FBLG profitable?
No. FibroBiologics Inc. reported a net loss of $18.14M for the twelve months ended Jun 30, 2026.How much cash and debt does FBLG have?
FibroBiologics Inc. reported $3.52M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is FBLG free cash flow?
FibroBiologics Inc. generated -$14.80M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$14.79M less capital expenditures.When did FBLG last report financial results?
The latest statements here come from FibroBiologics Inc.'s 10-Q filed on Jul 31, 2026, covering the period ended Jun 30, 2026.Where does this FBLG financial data come from?
Quantisnow builds these statements from the structured XBRL data FibroBiologics Inc. files with the SEC. It is provided for information only and is not investment advice.